Key result
Adipose mesenchymal stem cell-derived extracellular vesicles containing miR-192 alleviated inflammatory response and angiogenesis in diabetic retinopathy by targeting ITGA1.
Why the study?
Diabetic retinopathy features early capillary pericyte loss contributing to aberrant endothelial proliferation and angiogenesis, prompting investigation into mesenchymal stem cell-derived extracellular vesicles and microRNA-192.
Do MSC-derived extracellular vesicles containing miR-192 reduce inflammation and angiogenesis in models of diabetic retinopathy?
Do MSC-derived extracellular vesicles containing miR-192 reduce inflammation and angiogenesis in models of diabetic retinopathy?
MSC-derived extracellular vesicles containing miR-192 may offer a therapeutic approach for diabetic retinopathy by targeting ITGA1 to reduce inflammation and angiogenesis.
May inform MSC-EV therapies targeting angiogenesis in DR; hypothesis-generating and should not yet change practice.
Diabetic retinopathy (DR) has characteristics of early loss of capillary pericytes, contributing to aberrant endothelial proliferation and angiogenesis. The function of extracellular vesicles (Evs) derived from mesenchymal stem cells (MSCs) in angiogenesis and endothelial proliferation were investigated in the present study. In particular, the role of microRNA-192 (miR-192) was described. Firstly, the GSE60436 data set was applied to screen out that integrin subunit α1 (ITGA1) was overexpressed in DR. Subsequently, streptozotocin (STZ) was used to induce diabetes in rats, which was later subjected to intravitreal injection of targeted shRNAs. ITGA1 knockdown alleviated inflammation and angiogenesis in STZ-induced diabetic retina. Evs were extracted from MSCs and injected into rat vitreous. Meanwhile, human retinal microvascular endothelial cells, Müller cells, and retinal pigment epithelium cells were exposed to high glucose. MSC-derived Evs relieved inflammatory response and angiogenesis by shuttling miR-192. miR-192 targeted and negatively regulated ITGA1, thereby ameliorating diabetic retinal damage. Our study established that miR-192 released by Evs from MSCs could delay the events of the inflammatory response and angiogenesis in DR and may represent a possible therapeutic approach for the treatment of DR.
No takes yet. Share an insight, caveat, or question.
Gu et al. (2020) studied Diabetic retinopathy. Adipose mesenchymal stem cells-secreted extracellular vesicles containing microRNA-192 was evaluated on Inflammatory response and angiogenesis. Adipose mesenchymal stem cell-derived extracellular vesicles containing miR-192 alleviated inflammatory response and angiogenesis in diabetic retinopathy by targeting ITGA1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: